ReviewPrecision clinical medicine2025
Insights into the mechanisms of microRNAs in hepatoblastoma: from diagnosis to treatment.
Review in Precision clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pediatric Hepatoblastoma: From Developmental Molecular Mechanisms to Innovative Therapeutic Strategies.Cancers · 2026Review
- Upregulation of the lncRNACells · 2026Article
- Case Report: Hepatoblastoma with spindle cell sarcomatous metastasis in a 14-year-old girl.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatoblastoma (HB) is the most common malignant liver tumor in children. Early diagnosis and effective treatment are crucial for improving the prognosis of children with HB. In recent years, microRNAs (miRNAs), an important class of noncoding RNA molecules, have been increasingly recognized for their key regulatory roles in the occurrence, development, and treatment of HB. This review systematically reviews the expression characteristics, molecular mechanisms, and potential application value of miRNAs in the diagnosis and treatment of HB. Research indicates that the interaction network between miRNAs and long noncoding RNAs and circular RNAs has a significant effect on the development of HBs. miRNAs regulate signaling pathways, such as the Wnt/β-catenin, mitogen-activated protein kinase, phosphatidylinositol 3-kinase/protein kinase B, and Janus kinase 2/signal transducer and activator of transcription 3 pathways, and also play critical roles in the biological behavior of HBs. Furthermore, the progress of preclinical research on miRNAs as biomarkers and therapeutic targets provides new ideas and directions for precision medicine in HB. Finally, this article looks forward to the future development directions of miRNAs in precision medicine for HBs, emphasizing their important potential in improving diagnostic accuracy and treatment efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.